1-20 of 26
Authors: Johan Kros
Journal Article
MODL-36. EX VIVO GSC CULTURES RETAIN PATIENT-UNIQUE HALLMARK GENE EXPRESSIONS AND PREDICT PATIENT RESPONSE TO TMZ MORE SPECIFICALLY THAN MGMT PROMOTER STATUS Free
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v306–v307, https://doi.org/10.1093/neuonc/noad179.1187
Published: 10 November 2023
Journal Article
SURG-17. PROGNOSIS IN IDH-MUTANT GLIOMA: THE ROLE OF EXTENT-OF-RESECTION, AGE AND TUMOR GRADE Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii255, https://doi.org/10.1093/neuonc/noac209.983
Published: 14 November 2022
Journal Article
EPCO-17. METHYLATION ANALYSIS OF MATCHED PRIMARY AND RECURRENT IDHmt ASTROCYTOMA; AN UPDATE FROM THE GLIOMA LONGITUDINAL ANALYSIS NL (GLASS-NL) CONSORTIUM Free
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi5, https://doi.org/10.1093/neuonc/noab196.016
Published: 12 November 2021
Journal Article
PATH-27. MGMT PROMOTER STATUS IN IDH1/2 MUTANT ANAPLASTIC ASTROCYTOMA PATIENTS ASSESSED BY DNA METHYLATION PROFILING AND QMS-PCR: A REPORT FROM THE EORTC BRAIN TUMOR GROUP Free
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Pages vi120–vi121, https://doi.org/10.1093/neuonc/noab196.479
Published: 12 November 2021
Journal Article
LTBK-12. EORTC 26951, RANDOMIZED STUDY OF ADJUVANT PCV AFTER 59.4 GY RADIOTHERAPY: VERY LONG TERM FOLLOW-UP Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi285, https://doi.org/10.1093/neuonc/noz219.1201
Published: 22 November 2019
Journal Article
ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi14, https://doi.org/10.1093/neuonc/noz175.054
Published: 11 November 2019
Journal Article
SURG-30. CLINICAL COURSE OF IDH-MUTATED LOW-GRADE GLIOMAS DURING THE POSTSURGICAL ACTIVE MONITORING PHASE: ASYMPTOMATIC PATIENTS, WELL CONTROLLED SEIZURES, BUT CONTINUOUS GROWTH OF TUMOR RESIDUES Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Pages vi245–vi246, https://doi.org/10.1093/neuonc/noz175.1030
Published: 11 November 2019
Journal Article
ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi22, https://doi.org/10.1093/neuonc/noy148.079
Published: 05 November 2018
Journal Article
NIMG-75. WHO 2016 GRADE II GLIOMA MOLECULAR SUBTYPES HAVE A DISTINCT SPATIAL DISTRIBUTION PATTERN Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi192, https://doi.org/10.1093/neuonc/noy148.797
Published: 05 November 2018
Journal Article
PATH-42. EGFR-AMPLIFIED IDH-WILDTYPE GLIOBLASTOMAS SELDOM TRANSFORM INTO A HYPERMUTATED PHENOTYPE Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi168, https://doi.org/10.1093/neuonc/noy148.698
Published: 05 November 2018
Journal Article
IMMU-02. PROTEOMIC ANALYSIS IDENTIFIED CECR1 MEDIATED RESPONSE IN MACROPHAGE AND TUMOR ASSOCIATED MACROPHAGE Free
Neuro-Oncology, Volume 20, Issue suppl_2, June 2018, Pages i98–i99, https://doi.org/10.1093/neuonc/noy059.318
Published: 22 June 2018
Journal Article
HGG-04. PERICYTE-DERIVED PERIOSTIN IS CRUCIAL FOR NEO-VESSEL FORMATION IN GLIOMA Free
Neuro-Oncology, Volume 20, Issue suppl_2, June 2018, Page i89, https://doi.org/10.1093/neuonc/noy059.276
Published: 22 June 2018
Journal Article
LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410 Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi316, https://doi.org/10.1093/neuonc/nox213
Published: 17 November 2017
Journal Article
ANGI-18. PERIOSTIN IS EXPRESSED BY PERICYTES AND PROMOTES ANGIOGENESIS UNDER THE CONTROL OF GLIAL TUMOR CELLS Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi25, https://doi.org/10.1093/neuonc/nox168.096
Published: 06 November 2017
Journal Article
GENE-01. STABILITY OF ACTIONABLE MUTATIONS IN PRIMARY AND RECURRENT GLIOBLASTOMAS Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi92, https://doi.org/10.1093/neuonc/nox168.376
Published: 06 November 2017
Journal Article
PATH-51. OUTCOME IN 1p/19q NON-CO-DELETED GLIOMA TREATED AT FIRST RECURRENCE WITH TEMOZOLOMIDE W/WO BEVACIZUMAB IS DEPENDENT ON IDH, MGMT AND CIMP STATUS, BUT NOT ON GRADE AT FIRST DIAGNOSIS. A REPORT FROM THE RANDOMIZED PHASE II EORTC TAVAREC TRIAL Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi182, https://doi.org/10.1093/neuonc/nox168.740
Published: 06 November 2017
Journal Article
IMMU-56. T LYMPHOCYTES FACILITATE BRAIN METASTASIS OF BREAST CANCER BY EXPRESSIONAL IMPRINTING Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi125, https://doi.org/10.1093/neuonc/nox168.514
Published: 06 November 2017
Journal Article
PATH-53. EXPRESSION BASED INTRINSIC GLIOMA SUBTYPES ARE PROGNOSTIC IN LOW GRADE GLIOMAS OF THE EORTC22033-26033 CLINICAL TRIAL Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Pages vi182–vi183, https://doi.org/10.1093/neuonc/nox168.742
Published: 06 November 2017
Journal Article
SURG-05. THE IMPACT OF SURGERY IN MOLECULARLY DEFINED LOW-GRADE GLIOMA: AN INTEGRATED CLINICAL, RADIOLOGICAL AND MOLECULAR ANALYSIS Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi236, https://doi.org/10.1093/neuonc/nox168.962
Published: 06 November 2017
Journal Article
ACTR-04. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CO-DELETION, AN INTERGROUP TRIAL Free
Neuro-Oncology, Volume 18, Issue suppl_6, November 2016, Pages vi1–vi2, https://doi.org/10.1093/neuonc/now212.003
Published: 07 November 2016
